TSE:4502Pharmaceuticals
Does Zasocitinib’s Phase 3 Success in Hard-to-Treat Psoriasis Areas Change The Bull Case For Takeda Pharmaceutical (TSE:4502)?
In July 2026, Takeda reported positive Phase 3 results for its oral TYK2 inhibitor zasocitinib in adults with moderate-to-severe plaque psoriasis, showing rapid, durable skin clearance even in hard-to-treat areas such as the scalp, nails, palms and soles versus placebo.
By highlighting strong efficacy in high-impact, difficult-to-treat sites, the zasocitinib data point to a potentially differentiated psoriasis therapy within Takeda’s immunology pipeline.
We’ll now examine how zasocitinib’s...